
    
      This study is a national multicenter phase II prospective clinical trial to enroll low-risk
      breast cancer treat with breast-conserving surgery. All eligible patients will receive ABPI
      to a total dose of 40Gy, in 10 fractions, 4Gy/fx/day, within 2 weeks. Intensity modulated
      radiation therapy (IMRT) technique is used. During Follow up, the locoregional
      recurrence,survival,acute and late adverse events,and quality of life will be prospectively
      evaluated.
    
  